Skip to main content
Journal of the Endocrine Society logoLink to Journal of the Endocrine Society
. 2019 Apr 30;3(Suppl 1):SUN-452. doi: 10.1210/js.2019-SUN-452

SUN-452 Predictive Factors of Recurrence in Cushing's Disease after Successful Transsphenoidal Surgery

Vânia Gomes 1, Ana Gomes 1, Florbela Ferreira 1, Maria Bugalho 1
PMCID: PMC6553263

Abstract

Introduction: Successful long-term management in Cushing’s disease (CD) is challenging. Transsphenoidal surgery (TS) is the treatment of choice. Recurrence rates vary from 15–66% within 5-10 years of initially successful surgery. Objective: To evaluate the predictive factors for recurrence in patients with CD submitted to TS. Methods: Retrospective study of 44 patients with CD submitted to TS between 2005 and 2016 in a single tertiary center. Patients were divided into two groups, based on the outcome after TS (remission vs recurrence/persistence of disease), for comparison. Immediate postoperative remission (IPR) was defined as cortisol < 2ug/dL and ACTH <5 pg/mL within 7 days of tumor resection. Recurrence is defined by CD relapse after an initial remission after TS. Different variables were analyzed: age at diagnosis, gender, preoperative basal and dynamic hormonal tests and pituitary MRI, immediate postoperative hormonal tests, histological findings, postoperative hypopituitarism, time to recurrence, and time to recovery of hypothalamo-pituitary-adrenal (HPA) axis. Statistical analysis was performed with SPSS software, version 20. Statistical significance:&nbsp;p&nbsp;< 0.05. Results: From a total of 44 patients, 42 were eligible for the analysis and 2 were excluded due to unknown outcome after TS. The mean age was 40.6 ± 15 years and 90.5% were female. Based on immediate postoperative biochemical evaluation, performed in 35 individuals, only 18 (51,4%) would be considered in remission. Later clinical and biochemical evolution enabled considering 39 patients (92.9%) in remission. At a median follow-up of 6 years (1-21), 23 patients (59%) were still in remission whereas the remaining 41% relapsed; median time to recurrence – 3 years (0.25-17). Recurrence was significantly more frequent in: patients who needed glucocorticoid replacement therapy during less than 6 months after TS (19% vs 77.8%, p=0.004) and patients without histological evidence of adenoma/hyperplasia (75% vs 31%, p=0.04). There were no statistically significant differences between groups concerning the remaining variables studied. Conclusions: Absence of IPR criteria does not allow for conclusion of disease persistence. On the other hand, IPR is not a guarantee of life long remission. In this study, 41% of the patients who achieved surgical remission after TS recurred during long term follow-up making surveillance essential. Rapid recovery of HPA axis and negative histology were predictive factors of recurrence.


Articles from Journal of the Endocrine Society are provided here courtesy of The Endocrine Society

RESOURCES